News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Post Jobs
Submit a Press Release
Submit an Event
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Post Jobs
Submit a Press Release
Submit an Event
Search Query
Submit Search
News
Business
SurModics Inc. Announces Preliminary First Quarter 2012 Results
February 3, 2012
|
1 min read
Twitter
LinkedIn
Facebook
Email
Print
EDEN PRAIRIE, Minnesota--(BUSINESS WIRE)--SurModics, Inc. (Nasdaq:SRDX), a leading provider of surface modification technologies to the healthcare industry, announced today unaudited preliminary results for the first quarter of fiscal 2012.
Twitter
LinkedIn
Facebook
Email
Print
Earnings
MORE ON THIS TOPIC
Layoff Tracker
Amgen lays off around 40 employees
July 26, 2026
·
70 min read
·
BioSpace Editorial Staff
Drug Development
Sanofi’s $1.4B Kymab bet falters again as atopic dermatitis trials scrapped
July 24, 2026
·
3 min read
·
Gabrielle Masson
IPO
Scribe reels in nearly $129M in rare early-stage IPO for a gene editing biotech
July 24, 2026
·
3 min read
·
Tristan Manalac
Regulatory
Amgen deploys patients to defend troubled Tavneos in FDA hearing request
July 24, 2026
·
4 min read
·
Annalee Armstrong